BUSINESSCNBC TOP
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax secured $920 million in funding, enabling the French biotech company to prepare for an independent U.S. launch without relying on a buyer. The funds will cover operations through 2029.
Related Signal
Adjacent reporting
- As Honeywell Aerospace readies for its standalone debut, its CEO is forecasting big growth
- Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
- Anthropic files to go public as AI startups race to hit markets
- Blue Origin may need external funding to hit ambitious launch targets
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B